

Babesiosis

Name (last, first):					
Address (mailing):					
Address (physical): City/State/Zip: Phone (home): Alternate contact: Provider Information Phone: Phone:					
City/State/Zip: □ Hispanic or Latino □ Unk Phone (home): Phone (work/cell): Race: □ White □ Black/Afr. Amer. Alternate contact: □ Parent/Guardian Name: □ Spouse □ Other □ Mark all (Mark all that apply) □ Native HI/Other PI □ Unk PROVIDER INFORMATION Physician: Phone: □ Phone: □ Fax: □ Phone: □ Ph					
Phone (home): Phone (work/cell): Race: □White □Black/Afr. Amer. Alternate contact: □Parent/Guardian □Spouse □Other □Asian □Am. Ind/AK Native Name: Phone: that apply) □Native HI/Other PI □ Unk Physician: Physician: Phone: Fax:					
Alternate contact: ☐Parent/Guardian ☐Spouse ☐Other ☐Mark all ☐Masian ☐Am. Ind/AK Native ☐Am. Ind/AK					
Name:Phone:that apply)					
Physician: Phone: Fax:					
Physician: Phone Fax:					
Physician: Phone: Fax: Fax:					
Facility: Address:					
Addicss.					
City/State/Zip: Date reported to health department:/					
REPORTING SOURCE/HEALTHCARE PROVIDER (HCP)					
Report Source: Laboratory					
CLINICAL INFORMATION					
Onset date:/					
Clinical Findings Complications					
Y N U					
□ □ Fever □ □ □ Acute respiratory distress					
□ □ Anemia □ □ Disseminated intravascular coagulation (DIC)					
□ □ Thrombocytopenia □ □ □ Congestive heart failure (CHF)					
□ □ Headache □ □ □ Myocardial Infarction					
□ □ Chills □ □ Renal failure					
□ □ Sweats □ □ □ Case is asplenic (If yes, date of splenectomy:/)					
□ □ □ Myalgia □ □ □ Other:					
□ □ Arthralgia □ □ Other: Hospitalization					
□ □ Other: Hospitalization □ □ □ □ Patient hospitalized for this illness					
If you be suited we was					
Admit date: / /					
Y N U Case received antimicrobial treatment for infection					
If yes, which drugs (check all that apply)? Death					
☐ Clindamycin ☐ Quinine ☐ Atovaquone ☐ ☐ ☐ Patient died due to illness					
☐ Azithromycin ☐ Other: If yes, date of death:/					
LABORATORY INFORMATION					
Laboratory confirmatory results					
Y N U					
☐ ☐ Identification of intraerythrocytic <i>Babesia</i> organisms by light microscopy in Giemsa, Wright, Wright-Giemsa stained blood smear ☐ ☐ Detection of <i>Babesia microti</i> DNA in a whole blood specimen by polymerase chain reaction (PCR)					
□ □ Detection of <i>Babesia Microti DNA</i> in a whole blood specimen by polymerase chain reaction (FCK)					
□ □ Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation					
□ □ Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation **Laboratory supportive results**					
□ □ Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation					
 □ □ Isolation of Babesia organisms from a whole blood specimen by animal inoculation Laboratory supportive results □ □ □ Demonstration of a Babesia microti IFA total Ig or IgG titer of ≥ to 1:256 (or ≥ 1:64 in epidemiologically linked blood donor or recipients) 					
□ □ Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation **Laboratory supportive results □ □ □ Demonstration of a **Babesia microti* IFA total Ig or IgG titer of ≥ to 1:256 (or ≥ 1:64 in epidemiologically linked blood donor or recipients) □ □ □ Demonstration of a **Babesia microti* immunoblot IgG positive results					
□ □ Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation **Laboratory supportive results □ □ □ Demonstration of a **Babesia microti* IFA total Ig or IgG titer of ≥ to 1:256 (or ≥ 1:64 in epidemiologically linked blood donor or recipients) □ □ □ Demonstration of a **Babesia microti* immunoblot IgG positive results □ □ □ Demonstration of a **Babesia divergens* IFA total Ig or IgG antibody titer of ≥ 1:256					

INFECTION TIMELINE					
		Exposure Po	eriod		
Instructions: Enter onset date in grey box. Count backward to	Days from onset	-28 days (Max incubation	-7 days (Min incubation)	Onset date	
determine probable exposure period.	Calendar dates:	_/_/	_//_	- /	
exposure period.		MM / DD / YYYY	MM / DD / YYYY		
EPIDEMIOLOGIC EXPOSURE	C	וווווין טטן דודו	WIIWI / DD / TTTT		
EPIDEIMIOLOGIC EXPOSORE	.5				
Y N U History of travel during exposure period (if yes, complete travel history below):					
Destination (city, sta	Destination (city, state, and country)		Date of Departure	Reason for travel	
L					
□ □ Exposure to wooded, brushy, or grassy areas (i.e. potential tick habitats) If yes, where (county and state):					
If yes: date:/					
□ □ □ Tick found on body					
If yes, where was patient when tick found (county and state):					
If yes, date found:/					
□ □ □ If yes, was tick found attached to body? □ □ □ Potential occupational exposure (i.e. outdoor work in potential tick habitats)					
If yes, enter occupation:					
,,					
Where did exposure most likely o	ccur? County:	State:	C	Country:	
PUBLIC HEALTH ISSUES	,	PL	BLIC HEALTH ACTIONS		
Y N U			N U		
☐ ☐ Identified by blood dono	☐ Identified by blood donor screening		☐ ☐ Notified blood or tissue bank or other facility where blood or		
\square \square Donated blood, organs, or tissues prior to symptom onset			organs were donated		
If yes, date of donation:/			□ □ Notified patient obstetrician		
If yes, donation agency:			□ □ Disease education and prevention information provided to		
If yes, what was donated?			patient and/or family/guardian		
□ □ □ Case is pregnant			reduce risk around home		
If yes, enter due date:/			□ □ Education or outreach provided to employer		
☐ ☐ ☐ Case knows someone had shared exposure and is currently			☐ ☐ Facilitate laboratory testing of other symptomatic persons who		
having similar symptoms			have a shared exposure		
☐ ☐ ☐ Epi link to another confirmed case of same condition			□ □ Patient is lost to follow-up		
☐ ☐ Case is part an outbreak					
□ □ □ Other:					
MATERIC					
WVEDDS					
Y N U □ □ □ Entered into WVEDSS (Entry date://) Case status: □ Confirmed □ Probable □ Suspect □ Not a case					
NOTES					
NOTES					